New hope for hepatitis b: 48-Week drug trial launches
NCT ID NCT07519330
First seen Apr 17, 2026 · Last updated May 06, 2026 · Updated 3 times
Summary
This study tests a new medicine called HH-006 in 45 adults with chronic hepatitis B. Participants will receive the drug for 48 weeks and then be followed up to see how well it lowers hepatitis B surface antigen (HBsAg) levels. The goal is to control the virus, not cure it, as ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.